1. Home
  2. CTNM vs HTT Comparison

CTNM vs HTT Comparison

Compare CTNM & HTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.47

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Logo High Templar Tech Limited American depositary shares each representing one Class A ordinary share

HTT

High Templar Tech Limited American depositary shares each representing one Class A ordinary share

N/A

Current Price

$2.99

Market Cap

412.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CTNM
HTT
Founded
2009
2014
Country
United States
China
Employees
N/A
262
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
480.5M
412.8M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
CTNM
HTT
Price
$13.47
$2.99
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
172.1K
166.5K
Earning Date
05-13-2026
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
0.46
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$4.14
Revenue Growth
N/A
N/A
52 Week Low
$3.57
$1.88
52 Week High
$16.33
$3.91

Technical Indicators

Market Signals
Indicator
CTNM
HTT
Relative Strength Index (RSI) 49.26 74.50
Support Level $11.62 $2.97
Resistance Level $15.57 $3.28
Average True Range (ATR) 0.72 0.10
MACD -0.06 0.10
Stochastic Oscillator 41.35 83.81

Price Performance

Historical Comparison
CTNM
HTT

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About HTT High Templar Tech Limited American depositary shares each representing one Class A ordinary share

High Templar Tech Ltd is an enabler of AI-driven technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities.

Share on Social Networks: